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It has been proposed that human embryonic stem
cells could be used to provide an inexhaustible sup-
ply of differentiated cell types for the study of disease
processes. Although methods for differentiating
embryonic stem cells into specific cell types have
become increasingly sophisticated, the utility of the
resulting cells for modeling disease has not been de-
termined. We have asked whether specific neuronal
subtypes produced from human embryonic stem
cells can be used to investigate the mechanisms
leading to neural degeneration in amyotrophic lateral
sclerosis (ALS). We show that human spinal motor
neurons, but not interneurons, are selectively sensi-
tive to the toxic effect of glial cells carrying an ALS-
causing mutation in the SOD1 gene. Our findings
demonstrate the relevance of these non-cell-autono-
mous effects to human motor neurons and more
broadly demonstrate the utility of human embryonic
stem cells for studying disease and identifying po-
tential therapeutics.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative
disease that specifically affects motor neurons in the spinal
cord and brain stem (Boille´e et al., 2006a; Lobsiger and Cleve-
land, 2007). The majority of patients diagnosed with ALS have
no family history of disease and are therefore classified as spo-
radic cases (Brown, 1997; Cole and Siddique, 1999). However, it
is increasingly clear that ALS in these individuals likely results
from complex interactions between their specific genetic
makeup and the environment (van Es et al., 2008; Landers
et al., 2008). As is the case for many neurodegenerative condi-
tions, there are rare monogenic forms of ALS that are inherited
in a simple Mendelian fashion (Brown, 1997; Cole and Siddique,
1999). Notably, a variety of mutations in the ubiquitously ex-
pressed Super Oxide Disumutase gene (SOD1) lead to a domi-
nant, inherited form of ALS. Introduction of these mutant alleles
of the SOD1 gene into mice and rats (Rosen et al., 1993; Nagai
et al., 2001) has allowed the modeling of this form of disease in
animals.CeThe muscle atrophy and paralysis that are the clinical hall-
marks of ALS are indisputably caused by the death of motor neu-
rons. However, the extent to which their demise is an intrinsic
process or instead caused by pathological interactions with
other cell types in the spinal cord has become an area of intense
investigation (Boille´e et al., 2006a; Lobsiger and Cleveland,
2007). The evidence suggesting that negative interactions be-
tween cell types within the spinal cord might directly contribute
to motor neuron loss was obtained from studies with chimeric
mice (Clement et al., 2003). In these experiments, it was found
that motor neurons harboring the mutant SOD1 gene were often
spared when surrounded by nontransgenic support cells, while
nontransgenic neurons in close proximity to mutant neighbors
were subject to degeneration (Clement et al., 2003).
Subsequently, specific deletion of the pathogenicSOD1 trans-
gene from individual cell types implicated in ALS pathology has
confirmed that themutant SOD1 protein canmodify disease pro-
cesses by acting through both motor neurons and microglia. Re-
moval of the SOD1 transgene from motor neurons was found to
substantially delay but not halt the onset of disease (Boille´e et al.,
2006b), while removal of the mutant SOD1 transgene from mi-
croglia was found to extend life span in the animals by prolonging
the disease’s symptomatic phase (Boille´e et al., 2006b).
In addition to microglia, astroglia have also been implicated as
mediators of motor neuron cell death in familial ALS. Coculture
studies carried out in vitro have shown that mutant astrocytes
carrying SOD1mutations have a toxic effect on wild-type mouse
motor neurons (Di Giorgio et al., 2007; Nagai et al., 2007) and that
this effect is more severe in mouse motor neurons harboring the
SOD1 mutation (Di Giorgio et al., 2007). The relevance of this
finding has also been confirmed in vivo: specific deletion of the
mutant SOD1 gene from astrocytes, within otherwise transgenic
animals, substantially slows the progressive phase of the dis-
ease (Yamanaka et al., 2008). The discovery that cell types in
the spinal cord other than motor neurons play an important
role in ALS disease progression suggests that they may be tar-
gets for the development of ALS therapeutics.
Although these recent findings, enabled by mouse genetics,
have provided amore sophisticated understanding of the cellular
andmolecular mechanisms that may contribute to familial ALS, it
is critical to determine the relevance of these findings to human
motor neurons and eventually human patients. Unfortunately, it
has been impossible to isolate viable human motor neurons
from patients or from post mortem samples, preventing valida-
tion of findings from animal models of ALS. A widely proposedll Stem Cell 3, 637–648, December 4, 2008 ª2008 Elsevier Inc. 637
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use human embryonic stem cells as a renewable source of motor
neurons (Lensch and Daley, 2006; Ben-Nun and Benvenisty,
2006; Rubin, 2008).
Human embryonic stem cells have the capacity to self-renew
indefinitely in culture while maintaining their potential to gener-
ate virtually any cell type in the body (Murry and Keller, 2008).
In the last decade, since the initial derivation of human embry-
onic stem cells (Thomson et al., 1998), methodologies for direct-
ing their differentiation into specific cell types have become
increasingly sophisticated. (Murry and Keller, 2008). However,
to date there is still no evidence that these protocols can be
used to generate an adequate supply of the cell for disease
modeling, or that these cells will display appropriate disease rel-
evant phenotypes or cell-type-specific sensitivities to disease
stimuli.
Here, we examine the utility of specific neuronal subtypes,
including spinal motor neurons, derived from human ESCs for
investigating the disease mechanisms leading to ALS and the
identification of small molecules that can counteract their ef-
fects. We have developed a method for large-scale production
of motor neurons from human embryonic stem cells and used
them in coculture experiments to determine whether they were
selectively sensitive to the toxic, non-cell-autonomous effect of
glial cells harboring amutant allele of the SOD1 gene. Our results
demonstrate that human motor neurons are selectively sensitive
to this toxic effect, while interneuron populations produced from
embryonic stem cells are unaffected.
We also found that the specific toxicity to motor neurons was
associated with several significant changes in glial gene expres-
sion. These changes in gene expression were used to inform the
selection of several candidate molecules, which were screened
to determine whether they might potentially be involved in the
toxic effect of mutant glia. None of the molecules tested had
a significant effect on motor neuron survival except prostaglan-
din D2. When prostaglandin D2 was added to motor neurons
cocultured with normal glia, there was a significant reduction in
motor neuron survival. Furthermore, an inhibitor of prostaglandin
signaling significantly reduced the toxic effect that mutant glial
cells have on motor neurons.
These findings validate the toxic interactions between glial
cells and motor neurons as an important target for the develop-
ment of ALS therapeutics, while more generally demonstrating
the utility of human embryonic stem cells for producing a robust
supply of a specific cell type for disease modeling and drug
discovery.
RESULTS
In Vitro Differentiation of Human ESCs
into Motor Neurons
To generate a supply of spinal motor neurons from human ESCs
for the study of ALS, we adapted a recently reported method for
the production of these cells within embryoid bodies (EBs) (Singh
Roy et al., 2005) (Figure 1A). Undifferentiated, self-renewing
HuESCs (Cowan et al., 2004) were dissociated into small clumps
using collagenase treatment and then allowed to spontaneously
differentiate in suspension for 14 days (Figures 1A and 1B).
Staining with the neuronal progenitor marker PAX6 (Figure 1B)638 Cell Stem Cell 3, 637–648, December 4, 2008 ª2008 Elsevier Insuggested that a substantial percentage of the resulting EBs
(29% ± 16%; Figures 1C and 1D) contained cells differentiating
down the neuronal lineage. To direct these progenitors toward
a spinal motor neuron identity, we cultured the EBs another
14 days in the presence of retinoic acid (RA) and a small-mole-
cule agonist of the sonic hedgehog (SHH) pathway (Experimen-
tal Procedures). Under the influence of these morphogens, the
population of PAX6-positive progenitors expanded (45%± 15%;
Figures 1B–1D), and expression of the ventral progenitor marker
NKX6.1 and the motor neuron marker ISL1/2 was induced
(Figures 1B–1D). To promote motor neuron differentiation and
survival, we then transferred these 28-day-old EBs to media
containing neurotrophic factors for a final 14 days. At 42 days
of differentiation, the number of progenitors expressing PAX6
and NKX6.1 had begun to decline (Figures 1C and 1D), while
the number of cells expressing ISl1/2 continued to increase (Fig-
ures 1B–1D). At this time point, the HB9 transcription factor,
which is expressed in maturing postmitotic motor neurons,
was detected in 8% of all cells (Figures 1B–1D). When plated
on laminin, these EBs elaborated a dense network of neuronal
processes (Figure 1B).
To further characterize the putative motor neurons contained
within these EBs, the 42-day-old EBs were dissociated with pa-
pain, and the resulting cells were plated directly onto glial mono-
layers prepared from the cortex of neonatal mice (see Figure S1
available online). Costaining of cells with antibodies specific to
a neuronal form of tubulin (Tuj1) and the transcription factors
HB9 and ISL1/2 (Figures 2A and 2B), as well as costaining for
HB9 and choline acetyltransferase (ChAT) (Figure 2C), confirmed
that the HB9-positive cells within the EBs had differentiated into
motor neurons.
To further demonstrate that the appearance of these motor
neurons within the EBs were dependent on the influences of
RA and SHH, we repeated our differentiation scheme in the ab-
sence of one or both of thesemorphogens and counted the num-
ber of HB9-positive cells (Figure 2D). When SHH or RA activity
was removed individually, the frequency of cells expressing
HB9 fell to 0.7% (±0.2%) and 1.1% (±0.5%) respectively. If
both signaling molecules were omitted, less than 0.2% of the
dissociated cells expressed HB9 (0.17% ± 0.07%).
We further confirmed the robustness of our approach for gen-
erating motor neurons by differentiating six independent human
ESCs lines and then quantifying the number of HB9-positive cells
within the resulting EBs (Figure 2E). We found that HuES1,
HuES3, HuES5, and HuES9 ESC lines all differentiated into
HB9-expressing motor neurons with a similar efficiency (HuES
1, 7.1% ± 1.8%; HuES 3, 8.5% ± 0.5%; HuES 5, 4.7% ± 0.8%;
HuES 9, 7.7% ± 1.5%), while HuES 12 cells differentiated at
a lower efficiency (2.8% ± 1.3%) and HuES13 cells at a higher
efficiency (13.9% ± 3.8%). In addition to demonstrating the ro-
bust nature of this protocol for generating spinal motor neurons,
our results support the recent observation that some human ESC
lines can have varying propensities for differentiating into certain
cell types (Osafune et al., 2008).
A Transgenic hESC Line Reporting on Motor Neuron
Differentiation
In order to reproducibly identify living motor neurons in cultures
of differentiating human ESCs, we generated a stable transgenicc.
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cent protein (GFP) were under the control of the murine Hb9
promoter (Wichterle et al., 2002) (Figure 3) (see Experimental
Procedures). To validate that this transgenic cell line accurately
reported HB9 transcription, we differentiated the cells, plated
them on glial monolayers, and costained with antibodies specific
to GFP and HB9. Consistent with accurate reporting on HB9
expression, HB9 protein was detected in 95% of GFP-positive
cells (Figures 3C and S2A–S2D). We next investigated whether
Figure 1. Differentiation of Human ESCs
into Motor Neurons
(A) Diagram outlining the protocol used to differen-
tiate human ESCs into motor neurons. Undifferen-
tiated human ESC colonies are dissociated in col-
lagenase and grown as EBs for the first 14 days in
EB media, then are induced to a rostrocaudal
identity with retinoic acid (RA) and Shh for another
14 days. Finally, EBs are matured in the presence
of GDNF for 14 more days. At this point the EBs
can either be plated whole or dissociated with
papain and then plated.
(B) Immunohistochemistry was performed to de-
tect neuronal markers PAX 6, NKX 6.1, ISL1/2,
andHB9 in EB sections at 14, 28, and 42 days after
collagenase treatment of undifferentiated human
ESCs.
(C) Percent of sectioned EBs (n = 20) staining pos-
itive for PAX6, NKX6.1, ISL1/2, or HB9 at day 0,
day 14, day 28, and day 42 of differentiation.
(D) Percent of cells per sectioned EB (mean ± SD;
n = 3; cells counted in sections randomly selected
from different EBs) staining positive for PAX6,
NKX6.1, ISL1/2, or HB9 at day 0, day 14, day 28,
and day 42 of differentiation.
these GFP-positive cells expressed other
markers of a maturing motor neuron
identity (Figures 3 and S2). We observed
GFP expression in a subset of NKX6.1-
positive cells (Figure S2F) but observed
no GFP coexpression with NKX2.2
(Figure S2E), confirming that GFP-
positive cells had acquired the correct
dorsal-ventral identity (Jessell, 2000). Ad-
ditionally, these cells expressed ISL1/2
(Figure 3E) and ChAT (Figure 3F) but
no longer expressed the progenitor
marker PAX6 (Figure 3D). Antibody cos-
taining experiments also demonstrated
that GFP-positive cells did not coex-
press markers found in other neuronal
subtypes, such as the interneuron
markers LHX2 (Figure S2G) and CHX10
(Figure S2H).
The data that we have described thus
far confirm that it is possible to reproduc-
ibly generate a large supply of human
motor neurons from embryonic stem cells
and extend these findings by generating
an HB9::GFP transgenic human ESC line that can be routinely
used for the vital visualization of human motor neurons.
Human Motor Neurons Are Sensitive to the Toxic
Effect of SOD1G93A Glial Cells
To test whether the human spinal motor neurons we produced
were useful for investigating disease processes, we asked
whether they were sensitive to the toxic effect of glial cells
overexpressing a mutant SOD1 gene product. We dissociatedCell Stem Cell 3, 637–648, December 4, 2008 ª2008 Elsevier Inc. 639
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per well) on primary cortical glial monolayers derived from either
SOD1G93A transgenic or control mice (Figure 4A). After 10 days
a significant difference (p < 0.05) in the number of HB9-positive
motor neurons was seen between the two culture conditions
(Figure 4B). In cultures containing SOD1G93A glia, there were
less than half as many motor neurons (131± 53, n = 3) as in cul-
tures containing nontransgenic control glia (269 ± 44, n = 3)
(Figure 4B). The deficit in motor neuron survival in cocultures
with SOD1G93A glia became even more pronounced after
20 days (Figures 4C and 4D). A similar effect on survival of human
ESC-derived motor neurons was observed when they were cul-
tured for 20 days with media conditioned by SOD1G93A glia
(Figures S3A and S3B).
We next investigated whether the deficit in the number of mo-
tor neurons found on SOD1G93A glia was due to an initial re-
duced plating efficiency of these cells or instead was due to
some negative effect of the mutant glial cells that acted over
time to induce motor neuron loss. To this end we derived motor
Figure 2. Characterization of Human ESC-
Derived Motor Neurons
(A–C) Expression of neuronal markers ISL1/2 (A),
HB9 (B), and choline acetyltransferase (ChAT) (C)
in motor neurons derived from human ESCs.
(D) Percentage of cells immunoreactive for HB9
after treatment with or without RA and Shh
(mean ± SD; n = 3).
(E) Percentage of cells immunoreactive for HB9/
DAPI after 42 days of differentiation in different
HuESC lines (mean ± SD; n = 3; cells counted in
sections randomly selected from different EBs).
neurons from the Hb9::GFP human ESC
line, plated them at the same concentra-
tion (3 3 104 [n = 3] cells per well) on
SOD1G93A and nontransgenic control
glia, and then compared the number of
GFP-expressing motor neurons in these
two culture conditions 2, 10, and 20
days later (Figure 4E). At 2 days after plat-
ing, we did not find a significant differ-
ence between the number of motor neu-
rons in the two cocultures (Figure 4E),
arguing against a difference inmotor neu-
ron plating efficiency. However, at both
10 and 20 days there was a significant
decrease in the number of motor neurons
in coculture with SOD1G93A glia relative
to identical preparations of neurons
cocultured with control glia (57% ± 5%
and 42% ± 6%; p < 0.01) (Figure 4E).
We next addressed whether the toxic
effect of glia we observed in our initial ex-
periments was specific to the action of
themutant SOD1 protein rather than a re-
sult of SOD1 protein overexpression. Mo-
tor neuron preparations were generated
from the Hb9::GFP human ESC line and
cocultured for 20 days with nontransgenic glia or glia, which
overexpressed either the wild-type human SOD1 protein or the
mutant SOD1G93A protein (Figures 4F and 4G). There was no
discernable difference between the number of GFP-positive
motor neurons present in culture with the nontransgenic Glia
(304 ± 60, n = 3; Figures 4F and 4G) or with glia overexpressing
the wild-type SOD1 protein (328 ± 30, n = 3; Figures 4F and 4G).
In contrast, there was a highly significant reduction (p < 0.01) in
the number of GFP-positive motor neurons (127 ± 16, n = 3; Fig-
ures 4F and 4G) present in culture with the SOD1G93A glia, con-
firming that the non-cell-autonomous effect that we observed
wasmediated only through themutant form of the SOD1 protein.
Glial Toxicity Is Not Induced by Large-Scale
Protein Aggregation
In both patients and mice carrying mutant alleles of the SOD1
gene, intracellular aggregation of the SOD1 protein is often
documented and has been associated with motor neuron death.
We therefore wondered whether the toxic effect of glial cells640 Cell Stem Cell 3, 637–648, December 4, 2008 ª2008 Elsevier Inc.
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consequence of large-scale protein aggregation within the glial
cells. To address this question, we separately cultured primary
mouse glia and mouse ESC-derived motor neurons carrying
the same SOD1G93A transgene and stained the resulting cul-
tures with antibodies specific for the human SOD1 protein. As
we previously reported (Di Giorgio et al., 2007), after 21 days in
culture, the SOD1 protein inmousemotor neuronswas observed
to aggregate into large cytoplasmic and perinuclear inclusions
(Figure S4A). In contrast, even after more than 90 days in culture,
Figure 3. Characterization of the Hb9::GFP Human ESC Line
(A) DNA construct used for the electroporation of human ESCs.
(B) GFP expression during different stages of the differentiation from human
ESCs into motor neurons.
(C–F) Expression of neuronal markers HB9 (C), PAX6 (D), ISL1/2 (E), choline
acetyltransferase (ChAT) (F) in motor neurons derived from Hb9::GFP human
ESCs.Cethe SOD1 protein was found to be broadly and diffusely localized
in the cytoplasm of all glial cells (Figure S4B). These results imply
that the mutant protein is mediating its effect in these cells
through a mechanism independent of the large-scale protein
aggregation that is observed in motor neurons.
Motor Neurons Are the Selective Target of Glial Toxicity
ALS leads to the specific degeneration of motor neurons. There-
fore, if the toxic effect of glial cells that we have observed is rel-
evant to ALS, then wemight expect that other spinal cord neuro-
nal types such as interneuronswould be resistant to it. During our
characterization of human ESC-derived motor neurons, we
noted that additional neurons expressing the transcription fac-
tors CHX10 and LHX2, indicative of V2 and D1 interneuron iden-
tities, were also produced (Figures S2G and S2H). To test
whether these neuronal types were affected by coculture with
mutant glia, we dissociated 42-day-old EBs, plated equal num-
bers of cells on either SOD1G93A glia or nontransgenic glia
(Figure 5A) and after 20 days of culture stained for Tuj1 and either
LHX2 (Figures 5B and 5C) or CHX10 (Figures 5D and 5E). In strik-
ing contrast to the sensitivity of motor neurons to this environ-
ment, we found that neurons expressing these interneuron
markers were unaffected by culture with mutant glia (Figures
5B and 5D). Similarly, human ESC-derived interneurons cultured
for 20 days with SOD1G93A glia-conditioned media were
unaffected (Figures S3C and S3D).
Motor Neurons Are Unaffected by Fibroblasts
Expressing Mutant SOD1
To determine if the toxic effect of mutant glial cells was the con-
sequence of a specific activity within this cell type rather then
a general property of any cell overexpressing the SOD1G93A
mutation, we plated motor neuron preparations on mouse em-
bryonic fibroblasts (MEFs) prepared from SOD1G93A and non-
transgenic sibling embryos (Figure 6A). After 20 days of cocul-
ture, we did not observe a significant difference between the
number of HB9, Tuj1 double-positive neurons in these two con-
ditions (SOD1G93A MEFs, 204 ± 28 [n = 3]; or nontransgenic
MEFs, 197± 23 [n = 3]) (Figures 6B and 6C), consistent with the
hypothesis that astrocytes are specifically responsible for the
non-cell-autonomous effect we observed (Di Giorgio et al.,
2007; Nagai et al., 2007).
Identification of Candidate Genes Involved
in SOD1G93A Glial Toxicity
To better understand how the expression of a mutant gene that
causes ALS can perturb the normal phenotype of astrocytes,
and to identify genes that may have a role in their toxic effect
on motor neurons, we used oligonucleotide arrays to compare
the global gene expression profiles of glia overexpressing the
mutant SOD1G93A protein with two different sets of controls:
nontransgenic glia and glia overexpressing the wild-type form
of the human SOD1 protein.
We identified 135 genes whose expression was significantly
(p < 0.001) increased more than 2-fold in SOD1G93A glia when
compared to nontransgenic glia. Of these 135 genes, 53 were
exclusively upregulated in the mutant glia, and not in glia
overexpressing the WT SOD1 protein (Figure 7A), making them
interesting candidates for further investigation. We found thatll Stem Cell 3, 637–648, December 4, 2008 ª2008 Elsevier Inc. 641
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(A) Experimental design: embryonic stem cells were differentiated into motor neurons, and an equal number of cells (3 3 104 cells per well) were plated on two
different glial monolayers, one derived frommice overexpressing SOD1G93A, and the other derived from nontransgenic mice (WT). Motor neurons were counted
after 10 and 20 days in coculture.
(B) Number of HB9-positive cells 10 days after plating on SOD1G93A or nontransgenic (WT) glia (mean ± SD; n = 3).
(C) Number of HB9-positive cells 20 days after plating on SOD1G93A or nontransgenic (WT) glia (mean ± SD; n = 3).
(D) Images of HB9/Tuj1-positive cells 20 days after plating on SOD1G93A glia or nontransgenic (WT) glia.
(E) Percentage of Hb9::GFP cells remaining on SOD1G93A glia with respect to nontransgenic (WT) glia at 2, 10, and 20 days after plating (mean ± SD; n = 3).
(F) Number of Hb9::GFP cells 20 days after plating on SOD1G93A glia or nontransgenic (WT) glia or glia overexpressing the wild-type form of human SOD1
(SOD1WT) (mean ± SD; n = 3).
(G) Images of Hb9::GFP cells in the three different coculture conditions.13 of these 53 genes (24%) (Table S1) have previously been iden-
tified to have a role either in inflammatory or immune processes.
We narrowed our analysis to a subset of these genes deemed to
be of particular interest because of their known role as proinflam-
matory factors and their substantially increased expression in642 Cell Stem Cell 3, 637–648, December 4, 2008 ª2008 Elsevier Inmutant glia (Figure 7B). The prostaglandin D2 (PGD2) receptor
was upregulated more than 14-fold in SOD1G93A glia compared
to the control sample. Three different cytokines were also shown
to be overexpressed in mutant glia: Mcp2, Cxcl7, and Rantes.
Also found to be highly (>13-fold) upregulated in thesec.
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(GMFb), which has been shown to induce a proinflammatory
state in astrocytes (Zaheer et al., 2007). Finally, we found that
the expression of SHH and the SHH-responsive genes NKX2.2
andDBX2wasmodestly increased in themutant glia, suggesting
that this signaling pathway might be activated in response to the
actions of the mutant SOD1 protein.
Human ESC-Derived Motor Neurons Can Be Used
to Identify Neurotoxic Factors
In order to investigate the possible involvement of candidate
factors and signaling pathways in the glial-mediated neurotox-
icity we have observed, we tested the effect of these candidate
gene products, or molecules that activate them, on motor neu-
ron survival in cocultures with wild-type glial cells. Nontrans-
genic glia were individually pretreated for 1 day with either
one of the three cytokines MCP2, Cxcl7, or Rantes; GMFb;
an agonist of SHH pathway; or PGD2. After pretreatment of
the glial cells for 24 hr, a cellular preparation containing
Figure 5. Glia Cells Overexpressing SOD1G93A Do
Not Affect the Number of Interneurons
(A) Experimental design: embryonic stem cells were differenti-
ated intomotor neurons, and an equal number of cells (33 104
cells per well) were plated on two different glial monolayers,
one derived from mice overexpressing the mutation
SOD1G93A, and the other derived from nontransgenic mice
(WT). Human ESC-derived interneurons were counted after
20 days in coculture using two different markers, CHX10 and
LHX2.
(B) Number of LHX2-positive cells 20 days after plating on
SOD1G93A glia or nontransgenic (WT) glia (mean ± SD; n = 3).
(C) Image of LHX2/Tuj1-positive cells 20 days after plating on
SOD1G93A glia or nontransgenic (WT) glia.
(D) Number of CHX10-positive cells 20 days after plating on
SOD1G93A or nontransgenic (WT) glia (mean ± SD; n = 3).
(E) Image of CHX10/Tuj1-positive cells 20 days after plating on
SOD1G93A glia or nontransgenic (WT) glia.
Hb9::GFP human ESC-derived motor neurons
was plated on the glia. Replicate cultures were
individually maintained for 20 days in the presence
of each of the six factors and fixed, and the
numbers of GFP-positive motor neurons were
quantified.
We found that treatment with GMFb did not sig-
nificantly affect the number of human ESC-derived
motor neurons compared to the control condition
(95% ± 9%). Likewise, the presence of any one of
the three cytokines (Rantes, Cxcl7, and Mcp2) or
the SHH agonist did not seem to negatively affect
the number of GFP-positive motor neurons (re-
spectively 108% ± 20%; 102% ± 12%; 103% ±
8%; 97% ± 12%) (Figure 7C). However, when the
cells were treated for 20 days with PGD2, we found
a dramatic decrease in the number of motor neu-
rons compared to the control condition (19% ±
2%; p < 0.01) (Figures 7C and 7D), suggesting
that prostaglandin D2 signaling contributes to motor neuron
toxicity in this system.
Inhibition of the Prostaglandin D2 Receptor Partially
Rescues Motor Neuron Loss
To determine if there was a direct relationship between the toxic
effect of prostaglandin signaling on motor neurons and the
SOD1G93A glial-mediated neurotoxicity, we tested whether
a specific antagonist of the prostaglandin D2 receptor, MK
0524 (Sturino et al., 2007), could counteract or ameliorate the
toxic effect of mutant glia on motor neurons. SOD1G93A glia
and WT glia were pretreated for 1 day with the prostaglandin
D2 receptor inhibitor, human motor neurons were added, and
cultures were maintained for 20 days both in the presence and
absence of the drug. We found that the presence of MK 0524
did not affect motor neuron numbers when they were cocultured
with wild-type glia (100% ± 8%; Figure 7E). However, when hu-
man motor neurons plated on SOD1G93A glia were treated with
the inhibitor, there was a statistically significant (p < 0.05)Cell Stem Cell 3, 637–648, December 4, 2008 ª2008 Elsevier Inc. 643
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untreated neurons plated on the same glia) (Figures 7E and 7F).
These experiments suggest that inhibitors of PGD2 signaling do
not generally act to promote motor neuron survival and instead
act to specifically counteract the toxic effects of glial cells carry-
ing the ALS mutation.
DISCUSSION
Considerable time, effort, and expense would be saved if fun-
damental observations made in animal models could be rou-
tinely validated in the relevant human cell types (Gawarylewski,
2007; Rubin, 2008). However, the cells affected by disease are
often difficult, or in the case of human motor neurons impossi-
ble, to obtain from patients. A potential solution is to use hu-
man embryonic stem cells as a renewable source of these cells
for the study of disease and for preclinical drug target valida-
tion (Rubin, 2008; Sartipy et al., 2007; Pouton and Haynes,
2007; Klimanskaya et al., 2008). This notion that human ESC-
derived cells might be used to model disease processes has
been widely discussed (Lensch and Daley, 2006; Ben-Nun
and Benvenisty, 2006; Rubin, 2008); however, there has been
little demonstration that this approach is in fact feasible (Eiges
et al., 2007).
Tomore directly test the utility of human ESCs in diseasemod-
eling, we have produced large numbers of human spinal motor
neurons by in vitro differentiation and exposed them to condi-
tions known from both in vitro and in vivo studies to contribute
Figure 6. Mouse Embryonic Fibroblasts
Overexpressing SOD1G93A Do Not Affect
the Number of Motor Neurons
(A) Experimental design: embryonic stem cells
were differentiated into motor neurons, and the
same number of cells (3 3 104 cells per well)
were plated on two different mouse embryonic fi-
broblast (MEF) monolayers, one derived from
mice overexpressing the mutation SOD1G93A,
and the other derived from nontransgenic mice
(WT). Motor neurons were counted after 20 days
to compare the two conditions.
(B) Number of HB9-positive cells 20 days after
plating on SOD1G93A or nontransgenic (WT) MEF
(mean ± SD; n = 3).
(C) Image of HB9/Tuj1-positive cells 20 days after
plating onSOD1G93A or nontransgenic (WT)MEF.
to ALS disease progression. In order to
facilitate this investigation, we also gen-
erated a transgenic human ESC line that
enables identification of living human spi-
nal motor neurons. GFP-positive neurons
generated from this transgenic cell line
have an expression pattern indicative
of ventral identity (NKX6.1 positive;
NKX2.2 negative), motor neuron specific-
ity (HB9, ISL1/2 positive; CHX10, LHX2
negative), and maturation (PAX6 nega-
tive; ChAT positive), as seen in motor
neurons in vivo (Jessell, 2000; Arber
et al., 1999; Liem et al., 1997). This transgenic cell line will be
an invaluable tool for the purification and characterization of hu-
man motor neurons as well as for optimizing the production of
these neurons from hESCs.
We found that glial cells overexpressing the SOD1G93Amuta-
tion negatively affect the viability of human motor neurons in
a time-dependent manner. This non-cell-autonomous effect is
specific for motor neurons, as it does not seem to interfere
with the survival of human interneurons. Interestingly, we found
that the toxic effect on human motor neurons was even stronger
than the effect observed onmousemotor neurons. These results
not only further demonstrate the utility of the astrocyte coculture
system, but also validate the use of human ESC-derived motor
neurons as a powerful tool for the study of ALS and perhaps
other neuromuscular conditions.
To better understand the changes that expression of the SOD1
mutation induces in astrocytes, and to understand the roles of
these changes in motor neuron toxicity, we have carried out ge-
nome-wide expression profiling of glial cells overexpressing the
SOD1G93Amutation. We found that the SOD1mutation induces
a transcriptional signature in glia that is consistent with an inflam-
matory phenotype. This phenotype includes increases in prosta-
glandin D2 receptor expression, overexpression of proinflamma-
tory cytokines, and induction of other factors related to the
immune response. These findings confirm reports that link
a strong proinflammatory response to ALS in both animal models
and patients (Boille´e et al., 2006a; Almer et al., 2001; Kondo
et al., 2002).644 Cell Stem Cell 3, 637–648, December 4, 2008 ª2008 Elsevier Inc.
Cell Stem Cell
hESC-Derived Motor Neurons Sensitive to ALS GliaTo functionally test whether any of these inflammatory signals
could negatively affect motor neuron viability, we screened can-
didate molecules that activate these pathways using our wild-
type glial/motor neuron coculture system. Although most of
these compounds had no deleterious effect on motor neuron
survival, we found that treatment with prostaglandin D2 strongly
and significantly decreased the number of human ESC-derived
motor neurons in culture. The magnitude of this effect was strik-
ingly similar to that observed when motor neurons were cul-
tured with mutant glia. Remarkably, inhibition of the prostaglan-
din D2 receptor provided partial but significant protection to
motor neurons cultured with SOD1G93A glia, confirming that
this pathway contributes to the poisonous effect of mutant
glia. However, it remains unclear whether PGD2 toxicity is me-
diated through glial cells, or if it directly affects the viability of
motor neurons, or both.
Our results confirm previous evidence for the involvement of
prostaglandins and proinflammatory factors in ALS. In previous
reports, 15-deoxy-D12,14-PGJ2 (15d-PGJ2), a naturally occur-
ring derivative of prostaglandin D2, has been shown to accumu-
Figure 7. Identification of Prostaglandin D2
as a Toxic Factor for Human ESC-Derived
Motor Neurons
(A) Venn diagram presenting the overlap
among transcripts selectively overexpressed in
SOD1G93A glia and in SOD1WT glia with respect
to WT glia.
(B) Subset of genes overexpressed in SOD1G93A
glia but not in SOD1WT glia or WT glia.
(C) Percentage of Hb9::GFP cells remaining on
nontransgenic (WT) glia after 20 days of treatment
with GMFb, Rantes, Cxcl 7, Mcp 2, Shh, or PGD2
compared to the untreated condition (Ctrl) (mean ±
SD; n = 3).
(D) Image of Hb9::GFP-positive cells after 20 days
of treatment with prostaglandin D2 (PGD2) or with-
out treatment (Ctrl) on WT glia.
(E) Percentage of Hb9::GFP cells remaining onWT
glia or SOD1G93A glia after 20 days of treatment
with the inhibitor of prostaglandin D2 receptor
(MK 0524) (mean ± SD; n = 3).
(F) Image of Hb9::GFP-positive cells after 20 days
of treatment with the inhibitor of prostaglandin D2
receptor (MK 0524) or without treatment (Ctrl) on
SOD1G93A glia.
late in the spinal cord of sporadic ALS pa-
tients (Kondo et al., 2002). Levels of the
enzyme cyclooxygenase-2 (COX-2), one
of the key enzymes involved in the bio-
synthesis of PGD2, were also found to
be increased in the spinal cord of mouse
models and patients affected by ALS (Al-
mer et al., 2001; Kondo et al., 2002). Fur-
thermore, several reports have shown
a therapeutic effect of COX-2 inhibitors
in mouse models of ALS (Drachman and
Rothstein, 2000; Pompl et al., 2003; Kli-
venyi et al., 2004). Our results suggest
that it may be worthwhile to reconsider
molecules interfering with prostaglandin signaling as potential
therapeutic for ALS (Cudkowicz et al., 2006).
Consistent with the findings that we report here, the accompa-
nying manuscript by Marchetto et al. (2008) demonstrates that
human astrocytes expressing a mutant allele of the SOD1
gene, like their mouse equivalents, have a toxic effect on human
ESC-derived motor neurons. This effect seemed to be mediated
through activation of both secretory and inflammatory pathways.
Taken together, these studies suggest a scenario in which muta-
tion of SOD1 activates inflammatory pathways in astrocytes, in-
cluding activation of PGD2 signaling and nitric oxide release. It is
currently not clear whether PGD2 and nitric oxide work in the
same pathway or in parallel pathways. In the future, it will be in-
teresting to determine whether the inhibition of both pathways
can act synergistically to provide additional protection to motor
neurons in ALS.
More generally, our experiments support the hypothesis that
astrocytes play an active role in the demise of motor neurons
in ALS and demonstrate the relevance of this finding to human
motor neurons. These results also further highlight the negativeCell Stem Cell 3, 637–648, December 4, 2008 ª2008 Elsevier Inc. 645
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tant emerging target for the development of ALS therapeutics.
Importantly, we show that these experimental systems, which
rely on embryonic stem cells, can be used effectively to identify
factors involved in motor neuron degeneration as well as small
molecules that help protect them.
EXPERIMENTAL PROCEDURES
Growth of Human Embryonic Stem Cells
The HuESC lines were obtained from Doug Melton and cultured as described
by Cowan et al. (2004). The hESCs were maintained on a feeder layer of inac-
tivated mouse embryonic fibroblasts (GlobalStem) in human ESC media (KO-
DMEM (GIBCO), 10% KO Serum Replacement, 10,000 units penicillin, and
1mg/ml streptomycin (GIBCO), 2mMglutamine (GIBCO), 100 mMnonessential
amino acids (GIBCO), 55 mM beta-mercaptoethanol (GIBCO), 10% Plasma-
nate (Bayer), 10 ng/ml bFGF2 (GIBCO). The cells were cultured at 37C and
5% CO2. Media were replaced daily for the duration of hESC expansion,
and the cells in these conditions were passaged every 5–7 days using a solu-
tion with 0.05% trypsin (GIBCO).
Differentiation of Human Embryonic Stem Cells into Motor Neurons
ESCs were allowed to reach 80%–90% confluency, washed once with PBS,
and then incubated for 15 min at 37C in a solution of 1g/l Collagenase IV
(GIBCO) in DMEM-F12 (GIBCO).
ESC colonies were scraped and washed off the plate, centrifuged for 5 min
at 1000 RPM, and resuspended in human ESC media without bFGF2 or plas-
manate in low attachment 6-well plates.
After 24 hr, the cells had aggregated to form embryoid bodies (EBs), and the
mediawere changed to remove debris by centrifuging the EBs and resuspend-
ing in fresh human ESCmedia without bFGF2 or plasmanate in low attachment
6-well plates. EBs were cultured as such for 13 more days, with half of the me-
dia changed every 2 days, and a complete media change every week. After 14
days, the EBs were induced toward a caudal and ventral identity using retinoic
acid (1 mM, Sigma) and an agonist of the Shh signaling pathway (1 mM) in N2
media: 1:1 DMEM:F-12 + Glutamate (GIBCO), 10,000 units penicillin and
1mg/ml streptomycin (GIBCO), 1%N2Supplement (GIBCO), 0.2mMascorbic
acid (Sigma-Aldrich), 0.16% D-(+)-Glucose (Sigma-Aldrich), BDNF (10 ng/ml,
R&D Systems), for another 14 days. The EBs were then matured for a final
14 days in N2 media with GNDF (10 ng/ml, R&D Systems). EBs were fixed at
different stage, sectioned, and stained for different markers (Figures 1C, 1D,
and S1). For these experiments, sections of EBs randomly selected were
used for counting under fluorescence examination.
After 42 days of differentiation, the EBs were dissociated. To dissociate the
EBs, they were centrifuged at 1000 rpm for 5 min in a 15 ml falcon tube and
then washed once with PBS to eliminate residual media. The EBs were then
incubated for 60 min at 37C in Earle’s balanced salt solution with 20 units
of papain and 1000 units of Deoxyribonuclease I (Worthington Biochemical
Corporation). EBs were triturated using a 2 ml serological pipette every 15–
20 min during this incubation. The cell suspension was then filtered with
a 70 mm filter for eliminate residual big clumps and centrifuged for 5 min at
1000 RPM. The resulting cell pellet waswashed oncewith PBS and then resus-
pended in N2 media with neurotrophic factors (GDNF, and BDNF [10 ng/ml,
R&D Systems]). These cells were then counted and plated on Poly-D-Ly-
sine/Laminin CultureSlides (BD Biosciences) or on a layer of primary glial cells.
Depending on the experiment, motor neurons or interneurons were counted in
each well in its entirety at 203 under fluorescence examination, 10 or 20 days
after plating.
Generation of the HuES 3 Hb9::GFP Cell Line
HuES 3 cells were electroporated with a plasmid containing a neomycin resis-
tance cassette and the coding sequence of green fluorescent protein under
transcriptional control of a 9 kb murine Hb9 promoter restriction fragment.
The plasmid was a gift of Hynek Wichterle (Columbia University) and was
amodification of the construct described inWichterle et al. (2002). The electro-
poration was performed as described in Zwaka and Thomson (2003). Undiffer-
entiated HuES 3 cells were grown as described below. Once the cells reached646 Cell Stem Cell 3, 637–648, December 4, 2008 ª2008 Elsevier In80%–90% confluency, they were dissociated in trypsin and counted. Approx-
imately 1.03 107 were resuspended in 0.7 ml of human ESCmedia and mixed
with 0.1 ml of the samemedia containing 30 mg of linearized vector. This mix of
cells and DNAwas then transferred to a 0.4 cm cuvette and exposed to a pulse
of 320 V, 200 mF at room temperature. After 10 min at room temperature the
cells were plated on a 10 cm dish of MEF, and 48 hr after electroporation
the cells were switched to media containing G418 (50 mg/ml, GIBCO). Selec-
tion media were changed daily for 14 days, after which we picked and
expanded 24 resistant human ESC colonies. In order to assayGFP expression,
we differentiated six of these resistant clones intomotor neurons and immuno-
stained for GFP and HB9 coexpression. Two of these clones gave rise GFP-
positive cells that elongate green axons; however, only one clone was vali-
dated by immunoreactivity to the Hb9 antibody and used in subsequent
experiments.
Immunocytochemistry Analysis
Cells were fixed with 4% paraformaldehyde for 30 min at room temperature.
After fixation, the cells were washed three times with PBS for 10 min and
then treated for 1 hr in a blocking solution (PBS [Cellgro], donkey serum
[10%, Jackson Immunoresearch]) plus Triton X (0.1%, Sigma) for permeabili-
zation. After blocking, the cells were incubated overnight at 4C with primary
antibodies:mouse anti-b-tubulin III (Covance); rabbit anti-b-tubulin III (SIGMA);
Pax6, Nkx6.1, Nkx2.2, Isl 1, Hb9 (DSHB); Chx10, Lhx2 (Santa Cruz Technolo-
gies); ChAT (Chemicon); and rabbit anti-GFP conjugated Alexa Fluor 488 (Mo-
lecular Probes) in the blocking solution. After the overnight incubation the cells
were washed three times in PBS for 10 min. Localization of antigens was visu-
alized by incubating for 1 hr at room temperature using the respective second-
ary antibodies (Alexa Fluor 594 or 488; Molecular Probes). Finally, the samples
were washed again in PBS three times and mounted using a solution with or
without DAPI. Images were taken using a fluorescent Olympus IX70 micro-
scope.
Primary Glial Cultures
P1–P3 mouse pups transgenic for SOD1G93A or SOD1WT or nontransgenic
were sacrificed by using an approved method of euthanasia. Under a dissec-
tion microscope, the parenquima were isolated and the meninges were care-
fully stripped away with fine forceps. The tissue was then dissected into small
pieces and transferred to a solution containing 12ml of HBSS, 1.5 ml of trypsin
(GIBCO), and 1%DNase (Sigma) and incubated at 37C for 15min, swirling the
mixture periodically. The supernatant containing the dissociated cells was col-
lected, and 3 ml of serum was added to inhibit the trypsin.
Cells were then centrifuged at 1000 rpm for 5 min, resuspended in glia me-
dium [minimum essential medium with Earle’s salts (GIBCO), D-(+)-Glucose
20% (Sigma), penicillin-streptomycin (GIBCO), 10% horse serum (GIBCO)]
and plated at the concentration of 80,000 cells per ml in T75 flasks (Falcon).
After the glia reached confluency, theywere replated onto Poly-D-Lysine/Lam-
inin CultureSlides (BD Biosciences).
Treatments with Chemicals and Cytokines
Glia were pretreated for 1 day with either MCP2 (100 ng/ml; Peprotech), Cxcl7
(100 ng/ml; Peprotech), Rantes (100 ng/ml; Peprotech), GMFb (250 ng/ml; Pe-
protech), an agonist of Shh pathway (1 mM), PGD2 (10 mM; Chayman Chemi-
cal), or MK 0524 (10 mM;Chayman Chemical). After the pretreatment, a cellular
preparation containing Hb9::GFP human ESC-derived motor neurons, disso-
ciated from EBs, was added to the glia at the concentration of 30,000 cells/
well. The cells were then cocultured for 20 days in the presence of the com-
pounds and fixed, and the numbers of GFP-positive motor neurons were
quantified.
Microarray Analysis
Glia were derived from P1–P3mouse pups as described above. Once the cells
reached confluence, total RNA was isolated using Trizol (Invitrogen) from three
different biological replicates for each type of glia. RNA was amplified by one
round of T7 transcription using the Illumina TotalPrep RNA Amplification Kit,
and arrays were read by Illumina Bead Array Reader. Analysis was done using
the Illumina Bead Studio Program.c.
Cell Stem Cell
hESC-Derived Motor Neurons Sensitive to ALS GliaData Analysis
Statistical analysis was performed using Student’s t test, and data are
expressed as arithmetic mean ± SD; Student’s t test values of *p < 0.05,
**p < 0.01 were considered statistically significant.
ACCESSION NUMBERS
Microarray data have been deposited in the Gene Expression Omnibus (GEO;
http://www.ncbi.nlm.nih.gov/geo/) with the accession number GSE13643.
SUPPLEMENTAL DATA
The Supplemental Data include four figures and one table and can be found
with this article online at http://www.cellstemcell.com/supplemental/S1934-
5909(08)00522-5.
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